SETD2 and neoplasm: Consistent with these observations and previous lung cancer mouse modeling studies (Walter et al., 2017; Rogers et al., 2018; Xie et al., 2023), we find that Setd2 ablation strongly accelerates LUAD malignant progression and lethality in a KRASG12C-driven mouse tumor model (see Figure 1).